https://go.evvnt.com/915880-0?pid=5248 Hyatt Regency Boston
1 Avenue de Lafayette
Boston, Massachusetts 02111
Lectures & Conferences
As SGLT2 inhibitors redefine standard of care, opportunities to establish efficacy with surrogate endpoints take a step forward, and molecular phenotyping of disease etiology enables reclassification of patients to clinically actionable subtypes; drug development for chronic kidney disease has never been more exciting.
The 4th Chronic Kidney Disease Drug Development Summit (previously CKD3) is your only industry-led event dedicated to accelerating the frontier of preventative and regenerative therapies to meaningfully target kidney disease and enlighten opportunities for indication expansion into rare renal disorders. Uniting 100+ industry heavyweights including AstraZeneca, Johnson and Johnson, Bayer, Boehringer Ingelheim, Novartis, Otsuka, Novo Nordisk, and many more, this is a conversation you cannot afford to miss.
From dissecting pivotal insight into implementing patient stratification to turn the tide on precision medicine, to the brand-new seminar dedicated to establishing a pathway to clinical success in AKI, this is the only end-to-end forum presenting scientific advancements as actionable insights.
We hope to see you in Boston this March to together discover opportunities to personalize organ-on-a-chip technology and explore advances in stem cell platforms to regenerate kidney tissue. Leave this meeting equipped to guide your strategic decisions for 2022 and implement evolving surrogate endpoints of eGFR slope, albuminuria, and real-world evidence into innovative trial design.
Conference + Workshop Day - Drug Developer: USD 4096.0,
Conference + Seminar Day - Drug Developer: USD 3797.0,
Conference Only - Drug Developer: USD 3199.0,
Conference + Workshop Day - Solution Provider: USD 4996.0,
Conference + Seminar Day - Solution Provider: USD 4597.0,
Conference Only - Solution Provider: USD 3799.0,
Conference + Workshop Day - Academic: USD 2696.0,
Conference + Seminar Day - Academic: USD 2497.0,
Conference Only - Academic: USD 2099.0
Speakers: Agnes Benardeau Senior Director, Head of Cardio-Renal Biology, Novo Nordisk, Alan Glicklich, Chief Medical Officer, Chinook Therapeutics, Alan Yu, Professor and Kidney Institute Director, University of Kansas Medical Center, Alex Duncan, Chief Scientific Officer, Walden Biosciences, Aliza Thompson, Deputy Director of the Division of Cardiology and Nephrology, FDA, Andrew King, Chief Scientific Officer, Chinook Therapeutics, Anna Reznichenko, Senior Director, Team Lead Experimental Medicine, AstraZeneca, Anthony Johnson, President and Chief Executive Officer, Goldfinch Bio, Brad Rovin Director, Division of Nephrology, Ohio State University, Bruce Molitoris, Distinguished Professor of Medicine and Physiology, Indiana University, Chirag Parikh Director, Division of Nephrology, Johns Hopkins University, Cibele Pinto, Director, Global Medical Affairs, Otsuka, Dermot Reilly Director, Genetics and Translational Biology, Johnson and Johnson, Di Feng, Assistant Professor of Medicine, Harvard Medical School, Fredrik Erlandsson, Vice President, Head of Global Clinical Development, Vifor Pharma, Gary Friedman, Director, Inflammation and Immunology Pfizer, Hiddo Heerspink, Professor, University of Groningen, Hideo Makimura, Vice President and Head, Translational and Experimental Medicine, Cardiovascular and Metabolism Therapeutic Area, Johnson and Johnson, Ivan Formentini, Scientific Vice President and Head of Translational Science, Novo Nordisk, Janet van Adelsberg, Vice President, Research and Development, GlaxoSmithKline, Jeff Jacobs, Chief Scientific Officer, Ardelyx, Jeffrey Hafkin, Senior Director, Otsuka, Jerome Rossert, Vice President, Head of Clinical Renal, AstraZeneca, John Liles, Director, Biology, Gilead Sciences, Jonathan Barratt, The Mayer Professor of Renal Medicine, University of Leicester, Joseph Bonventre, Chief of the Division of Renal Medicine and Founding Chief of the Engineering in Medicine Division, Brigham and Women's Hospital, Julie Lin, Global Project Head, Clinical Development, Rare Diseases and Rare Blood Disorders, Sanofi Genzyme, Julie Williams, Director, Bioscience CKD, AstraZeneca, Kerry Willis, Chief Scientific Officer, National Kidney Foundation, Kevin Woollard, Director, AstraZeneca, LaToya Coffey, Senior Director, Global Development Team Leader, Otsuka, LaVarne Burton, President and Chief Executive Officer, American Kidney Fund, Maarten Kraan, Chief Medical Officer, AM-Pharma, Maria Chiara Magnone, Vice President Kidney Diseases and Boston Site Head, Janssen, Marie-Anne Valentin, Global Head Soluble, Biomarker Team, Novartis, Martin Lefkowitz, Vice President, Global Clinical Research and Development, Novartis, Matthew Breyer, Distinguished Scientist, Johnson and Johnson, Matthias Kretzler, Professor of Internal Medicine and Bioinformatics, University of Michigan, Meg Jardine, Professor of Medicine, The University of Sydney, Michael Boettger, Vice President, Head Experimental Medicine CV, Bayer, Michael Spigler, Vice President, Patient Services and Kidney Disease Education, American Kidney Fund, Michelle Penny, Vice President, Head of Genomics, Goldfinch Bio, Nader Najafian, Executive Director, Clinical Development Sciences, Alexion, Nikolay Nikolov, Director of the Division of Rheumatology and Transplant Medicine, FDA, Pernille Laerkegaard, Hansen Executive Director, Head of Bioscience Renal, AstraZeneca, Richard Furie, Chief, Division of Rheumatology, Northwell Health, Richard Nkulikiyinka, Vice President, Head of Therapeutic Area Cardiology and Nephrology, Bayer, Sameer Bansilal, Executive Director, Cardiovascular and Renal, Bayer, Scott Rottinghaus, Vice President and Head Of Clinical Development, Hematology and Nephrology, Alexion Pharmaceuticals, Sven Moosmang, Therapeutic Area Head Translational Medicine and Clinical Pharmacology Cardiometabolism, Boehringer Ingelheim, Seemi Khan, Senior Vice President, Chief Medical Officer, Reata Pharmaceuticals, Uli Broedl, Senior Vice President, Head of Global Clinical Development and Operations, Boehringer Ingelheim, William Smith, Executive Director, Nephrology Clinical Development Sciences, Alexion